Lunit's Insight DBT gets certification from EU for medical device

The S.Korean medical company will start selling AI-based breast cancer 3D imaging analysis solution around the end of this month

Lunit's Insight DBT gets certification from EU for medical device
Ji-Hyun Lee 1
2023-03-20 16:30:37 bluesky@hankyung.com
Bio & Pharma


South Korean medical AI company Lunit said on Monday that its 3D breast tomosynthesis artificial intelligence (AI) image analysis solution, "Lunit Insight DBT",  has received Medical Device Directive (MDD) CE certification in the European Union (EU).


The company plans to start selling the device in Europe by the end of this month. The EU's MDR CE certification enhances the performance and quality standards of medical devices compared to the previous Medical Device Directive CE making it essential for companies seeking to enter the European market as the sale of uncertified products will be prohibited from May 2024.

Lunit had previously acquired MDR CE certification for two other products, the chest X-ray AI image analysis solution "Lunit Insight CXR" and the mammography AI image analysis solution "Lunit Insight MMG."

Lunit Insight DBT analyzes 3D breast tomosynthesis images quickly and accurately, assisting healthcare professionals in diagnosing breast cancer. The company developed Lunit Insight DBT based on Lunit Insight MMG. 3D DBT allows for more sophisticated testing than conventional 2D breast imaging and is in high demand in advanced medical institutions in countries such as the US and Europe.

At the "European Congress of Radiology 2023" held in Vienna, Austria, earlier this month, the company presented a research abstract related to Lunit Insight DBT. The company analyzed the accuracy and performance of breast cancer detection for 162 women with an average age of 52 who underwent examination at domestic advanced medical institutions.

The results showed that Lunit Insight DBT demonstrated accuracy comparable to that of experienced radiologists with more than ten years of experience.

"We are ready to sell Lunit Insight DBT in Europe, and we plan to expand sales to other global markets, including the US and Australia, which comply with European regulations," said Lunit CEO Suh Beom-seok.

Lunit also plans to pursue approval procedures for Lunit Insight DBT in the US, the world's largest medical device market, within this year.

Write to Ji-Hyun Lee at bluesky@hankyung.com

Lunit to supply AI image analysis solutions to Singapore

 Lunit to supply AI image analysis solutions to Singapore

Lunit's Insight CXR South Korea's Lunit Inc., an artificial intelligence (AI) medical company, announced on Wednesday that it has secured a contract to provide Lunit Insight CXR, an AI image analysis solution for chest X-rays, to Singapore's Radlink Imaging Center, an imaging diagnosis medical

Lunit receives $1 mn in tech fees from Guardant Health of US

Lunit receives $1 mn in tech fees from Guardant Health of US

Lunit Scope PD-L1 The US operations of South Korea's artificial intelligence (AI) medical company Lunit have received a major boost after the company got the green light for use of its products at facilities requiring Clinical Laboratory Improvement Amendments (CLIA) certification, an American

AI medical software company Lunit to open subsidiary in Europe

AI medical software company Lunit to open subsidiary in Europe

South Korea's Lunit, an artificial intelligence (AI) medical software company, on Friday said its board meeting held on the previous day decided to open a subsidiary in Europe dubbed Lunit Europe Holdings.To be a wholly owned affiliate of Lunit, the Netherlands-based subsidiary will soon start

S.Korea's Lunit supplies breast cancer imaging solution to UAE

S.Korea's Lunit supplies breast cancer imaging solution to UAE

Lunit Insight MMG South Korean medical AI company Lunit has supplied its breast cancer imaging analysis solution — Agfa HealthCare Enterprise Imaging — to the United Arab Emirates' state-run Dubai Academic Health Corp., the company said on Thursday. The solution was developed in par

Lunit launches AI-based pathology analysis solution with US firm

Lunit launches AI-based pathology analysis solution with US firm

Lunit SCOPE PD-L1, an AI solution for detecting and analyzing cancer biomarker PD-L1 South Korea's medical imaging startup Lunit said on Wednesday that it has launched Guardant360 TissueNext, an AI-based pathology analysis solution developed in collaboration with America's precision oncology co

(* comment hide *}